- NCIt
- C40156
Loading cancer entity…
Loading cancer entity…
Clinical trials
17 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03120624 | VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer | active not recruiting | Phase 1 | 34 | Mayo ClinicOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT02020707 | Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers | completed | Phase 1 | 43 | Mayo ClinicOTHER | 1 | Jul 26, 2024 | clinicaltrials |
| NCT01935973 |
| Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer |
| completed |
| Phase 1 |
| 26 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Oct 14, 2020 |
| clinicaltrials |
| NCT01440998 | Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer | completed | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 1 | Apr 5, 2018 | clinicaltrials |
| NCT00575952 | Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer | completed | Phase 1 | 27 | Gynecologic Oncology GroupNETWORK | 1 | Aug 24, 2017 | clinicaltrials |
Data updated 22 days agoSource updated Jul 21, 2026source: clinicaltrials